Intellectual property (IP) is protected by various legal mechanisms such as patents, copyrights, trademarks, and trade secrets. These legal frameworks enable creators, inventors, and businesses to protect and profit from their ideas, inventions, and creative works.
Patents protect inventions, while copyrights protect creative works such as books, music, and art. Trademarks protect brands and logos, and trade secrets protect confidential business information. By protecting these types of intellectual property, creators and businesses can benefit financially and earn recognition for their work. While the IP system provides incentives for innovation, it must also promote competition and ensure that essential goods and services are accessible to everyone. A well-designed IP system can foster an environment in which creativity and innovation can flourish, while also promoting broader social and economic benefits.
Types of intellectual property
There are several types of intellectual property, each with its own set of rules and requirements for protection. The main types of intellectual property are: Patents, Trademarks, Industrial designs, Geographical indications, Trade secrets, Copyright
Patents - A patent is an exclusive right granted to an inventor or assignee for a limited period of time, typically 20 years from the filing date of the patent application. During this time, the patent owner has the right to exclude others from making, using, selling, or importing the patented invention without their permission. This means that the patent owner has the exclusive right to manufacture and sell the invention, or license others to do so, during the period of the patent.
In exchange for this exclusive right, the patent owner must disclose technical information about the invention in the published patent document. This enables others to learn from the invention and build upon it, once the patent has expired. The disclosure also contributes to the progress of science and technology, as others can use the information to develop new and improved products or processes. In this way, patents help to promote innovation and benefit society as a whole.
In the pharmaceutical industry, patents play a critical role in protecting the intellectual property rights of drug manufacturers. After the discovery of a new active substance, it is typically necessary to apply for a patent in order to meet the patentability criteria, especially the requirement for novelty and non-obviousness. This patent can provide the inventor with exclusive rights to make, use, and sell the drug for a limited period of time, typically 20 years from the date of filing the patent application.
It's worth noting that patents canot be granted for diagnostic or treatment methods themselves, as these are considered to be part of the practice of medicine and are not considered to be inventions. However, products that are used in conjunction with these methods can generally be patented. For example, a new drug that is used in the treatment of a particular disease can be patented, even if the method of treatment itself cannot be patented.
Additionally, it's possible to obtain first and second medical use patents for existing products. A first medical use patent can be granted for a known substance or drug when it's discovered that it can be used to treat a new condition. A second medical use patent can be granted for a known substance or drug when it's discovered that it can be used to treat a different aspect or stage of an existing condition. These types of patents are important for pharmaceutical companies as they allow them to protect their investments in research and development by providing exclusive rights to use an existing product in a new way.
Obtaining first and second medical use patents for existing products is an important strategy for pharmaceutical companies to protect their investments in research and development.,A first medical use patent is granted when a known substance or drug is discovered to have a new therapeutic application. For example, if a drug that was originally approved to treat high blood pressure is later found to also be effective in treating migraines, a first medical use patent can be granted for the new use of the drug. A second medical use patent is granted when a known substance or drug is found to be effective in treating a different aspect or stage of an existing condition. For example, if a drug that was originally approved to treat early-stage cancer is later found to also be effective in treating late-stage cancer, a second medical use patent can be granted for the new use of the drug. These types of patents are important for pharmaceutical companies because they provide them with exclusive rights to use an existing product in a new way. This allows them to recoup the investment they made in researching and developing the drug and to generate additional revenue by selling the drug for the new use. It also helps to incentivize further research and development in the field of medicine.
However, the time required to complete clinical trials, obtain regulatory approval, and bring a new drug to market can be lengthy, which can reduce the effective patent period for the drug. In recognition of this, various mechanisms have been developed to extend the effective patent period for drugs, such as patent term extensions and data exclusivity.
Patent term extensions allow for additional time to be added to the effective patent period for a drug, beyond the standard 20-year term. This can occur, for example, if the regulatory approval process takes longer than anticipated, or if a pediatric study is conducted. Patent term extensions are available in some countries, but the rules and requirements vary depending on the jurisdiction.
Data exclusivity, on the other hand, is a period of time during which regulatory authorities cannot rely on the data submitted by another company to support the approval of a generic version of a drug. This period of exclusivity is intended to provide an incentive for companies to invest in the development of new drugs by allowing them to recoup their research and development costs before facing competition from generic versions of the drug. The duration of data exclusivity also varies depending on the jurisdiction, ranging from a few years to up to 10 years in some cases.
Although regulation and the acquisition of intellectual property rights are separate from each other, there are also points of intersection. Equivalents of drugs whose patent protection period has expired can be produced. For these drugs, registration authorities accept shortened registration applications made by referencing the drug registration application file of the original drug manufacturer. Only here the data privilege period must have expired. Equivalent drug manufacturers cannot apply for a certain period of time following the registration date of the original drug manufacturers by referring to the data in the registration application file of the original drug that the original drug is effective, safe and of good quality. Even if the “Bolar Exemption” is accepted here and it is allowed to apply for a license, the drug will not be placed on the market. Even if a license has been obtained for the equivalent drug by applying for an abbreviated license, placing the drug on the market based on this license will violate the patent right of the original drug. On the other hand, the reason for the creation of data privilege is expressed as the shortening of the effective patent period for the above-mentioned reason.
It is important to keep the processes of regulation and intellectual property rights separate, as they serve different purposes and are governed by different legal frameworks. Regulatory authorities are responsible for ensuring that drugs are safe, effective and of good quality, while intellectual property rights provide legal protection for innovations and creations.
The evaluation of applications for regulatory approval and intellectual property rights should be based on different legal criteria and be carried out by different institutions to avoid any conflicts of interest or bias. For example, regulatory authorities may evaluate the safety, efficacy and quality of a drug based on data from clinical trials, while patent offices may assess the novelty, inventive step and industrial applicability of an invention.
It is important to maintain the separation between regulatory and intellectual property processes to ensure that innovations and creations are protected under intellectual property laws while also ensuring that safe and effective drugs are made available to patients in a timely manner.
Comentarios